Human cytosolic sulfotransferase SULT1C4 mediates the sulfation of doxorubicin and epirubicin
Authors:
- 1 April 2016
- journal article
- Published by Elsevier in Drug Metabolism and Pharmacokinetics
- Vol. 31 (2) , 163-166
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (R03HD071146)
This publication has 17 references indexed in Scilit:
- Risk‐stratified patients with resectable soft tissue sarcoma benefit from epirubicin‐based adjuvant chemotherapyCancer Medicine, 2014
- Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancerBreast Cancer Research, 2011
- Role of Anthracyclines in the Treatment of Early Breast CancerJournal of Clinical Oncology, 2009
- Developmental Expression of Aryl, Estrogen, and Hydroxysteroid Sulfotransferases in Pre- and Postnatal Human LiverThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Regulation of thyroid hormone metabolism during fetal developmentMolecular and Cellular Endocrinology, 1999
- Anthracycline-Induced CardiotoxicityAnnals of Internal Medicine, 1996
- Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumorsCancer, 1994
- Dehydroepiandrosterone sulfotransferase in the developing human fetus: quantitative biochemical and immunological characterization of the hepatic, renal, and adrenal enzymes.Endocrinology, 1994
- Epirubicin and doxorubicin comparative metabolism and pharmacokineticsCancer Chemotherapy and Pharmacology, 1988
- 4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical dataCancer Treatment Reviews, 1983